Author

Bob Warnock

Institution: Emergent BioSolutions (United States)

Observed institutions: Emergent BioSolutions (United Kingdom), Emergent BioSolutions (United States)

ORCID: 0009-0002-2259-4455

Observed ORCID: 0009-0002-2259-4455

OpenAlex ID: A5117188976

Brincidofovir in the Era of Mpox

2025 · James McCarty, David Cassie, et al. · Expert Review of Anti-infective Therapy · 11

A Phase 1, Open‐Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Participants

2026 · David Cassie, Bob Warnock, et al. · Clinical and Translational Science

A phase 1, first-in-human, open label, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite nasal spray in healthy adult participants

2025 · David Cassie, Mila Mirceta, et al. · Journal of Pharmacology and Experimental Therapeutics

Works count: 3

Citation count: 11

H-index: 1

I10-index: 1